الفهرس 
Estimation of serum autoantibody level to desmoglein-1 in oral lichen planus patients before and after treatment with corticosteroid therapy
LIST OF CONTENTSOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa. It affects between 0.5% and 4% of the adult population and has a higher prevalence in middle-aged females. The pathogenesis of OLP remains uncertain, but it is thought to arise from an immune response to a number of antigens within the oral epithelium. A variety of risks or predisposing risk factors have been identified for OLP, which include periodontal and gingival inflammation arising from deposits of plaque and calculus, hypersensitivity to amalgam and other metals, trauma to oral mucosa and stress. There is also evidence that in certain population, viruses (mainly hepatitis C) may be important in the immunopathogenesis of OLP. Different forms of OLP have been recognized, which relate to clinical appearance. The current classification describes three major forms: reticular {u2044} hyperkeratotic, atrophic {u2044} erythematous and ulcerative {u2044} erosive forms. The symptoms arising from OLP vary markedly and often relate to the specific category. Pain and soreness, which interfere with oral function, are more commonly associated with the ulcerative form. Other symptoms related to OLP include soreness on tooth brushing, burning mouth and oral discomfort arising from eating hot, cold or spicy food. A range of treatments have been evaluated in the management of OLP. Topical medications seem to be the most widely used; however, a Cochrane review failed to identify a superior agent for the management of this common condition. Despite this finding, many reviews of the treatment of OLP suggest that topical steroids are the most widely used. Eleven patients suffering from symptomatic oral lichen planus were included in the present study divided into two groups. Patient were divided randomly into two groups, before and after treatment with topical Triamcinolone acetonide (0.1% in orabase(